CEO, Cytox LtdBiography
Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 25 years. He has been CEO at Cytox for the past 7 years, a precision medicine working on developing and commercialising a new diagnostic technology for assessing Alzheimer's Disease risk. Prior to Cytox, Richard has held senior R&D and leadership positions in global pharmaceutical companies including GE Healthcare/Amersham plc, Lorantis and UCB-Celltech. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer's disease patients.